MME and renal cell carcinoma: Regarding the proximal tubular markers such as CD10 and CD13, immunolabeling for the former was observed in 26 of 33 (79%), 25 of 33 (76%), and 22 of 33 (67%) of the MiT family translocation renal cell carcinomas, with the respective increasing cutoffs.